Multiple endocrine neoplasia type 2: A review.
Mathiesen JS, Effraimidis G, Rossing M, Rasmussen ÅK, Hoejberg L, Bastholt L, Godballe C, Oturai P, Feldt-Rasmussen U.
Semin Cancer Biol. 2022 Feb;79:163-179. doi: 10.1016/j.semcancer.2021.03.035. Epub 2021 Apr 1.
CO-EXISTENT PHEOCHROMOCYTOMA AND THYROID CARCINOMA (SIPPLE'S SYNDROME).
KAYE RH, ZAK FG.
J Mt Sinai Hosp N Y. 1964 Nov-Dec;31:476-86.
Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.
Greenberg LA.
Prim Care. 2024 Sep;51(3):483-494. doi: 10.1016/j.pop.2024.03.006. Epub 2024 May 23.
Multiple endocrine neoplasia 2 (MEN 2)/MEN 2A (Sipple syndrome).
Kousseff BG.
Dermatol Clin. 1995 Jan;13(1):91-7.
[Sipple syndrome (review of foreign literature)].
Vetshev PS, Mel'nichenko GA, Kuznetsov NS, Vel'tsevich DG, Smirnov SV.
Khirurgiia (Mosk). 1996;(2):122-7.
Pheochromocytoma in MEN2.
Gild ML, Do K, Tsang VHM, Tacon LJ, Clifton-Bligh RJ, Robinson BG.
Recent Results Cancer Res. 2025;223:211-235. doi: 10.1007/978-3-031-80396-3_8.
[Sipple syndrome].
Vetshev PS, Mel'nichenko GA, Kuzhetsov NS, Ippolitov LI, Solov'eva NA.
Khirurgiia (Mosk). 1996;(5):59-60.
RET oncogene.
Mak YF, Ponder BA.
Curr Opin Genet Dev. 1996 Feb;6(1):82-6. doi: 10.1016/s0959-437x(96)90015-5.
Preemptive surgery.
McAuliffe PF, Cance WG.
Surgery. 2006 Jul;140(1):1-5. doi: 10.1016/j.surg.2006.01.009.
Age and MEN2 outcome.
Castinetti F.
Aging (Albany NY). 2019 Jun 12;11(11):3416-3417. doi: 10.18632/aging.102030.
